PODDNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
INSULET CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$141.96+0.86 (+0.61%)
Close on Oct 19, 2026
- Market cap
- $9.85B
- P/E (TTM)
- 26.5
- Dividend yield
- –
INSULET CORP revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Omnipod products | $2.67B | $2.03B | $1.66B | $1.25B | $1.01B | $834.90M | $673.50M | $495.50M | $391.60M | – | 98.7% | +31.5% |
| U.S. | $1.92B | $1.51B | $1.25B | $884.80M | $651.50M | $526.90M | $420.40M | $323.50M | $271.60M | $229.79M | 70.9% | +27.2% |
| International | $754.30M | $523.40M | $410.10M | $363.00M | $359.90M | $308.00M | $253.10M | $172.00M | $120.00M | $71.89M | 27.9% | +44.1% |
| Drug Delivery | $34.10M | $38.90M | $36.00M | $57.50M | $87.40M | $69.50M | $64.70M | $68.30M | $72.20M | $65.32M | 1.3% | -12.3% |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $1.95B | $1.55B | $1.29B | $942.30M | $738.90M | $596.40M | $485.10M | $391.80M | $343.80M | $295.10M | 72.2% | +26.2% |
| International | $754.30M | $523.40M | $410.10M | $363.00M | $359.90M | $308.00M | $253.10M | $172.00M | $120.00M | $71.89M | 27.9% | +44.1% |
From the segment and revenue-disaggregation notes of Insulet's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.